EBS
Emergent Biosolutions Inc
6.60$
-4.6%
vs. previous close
Closing price · As of: Sep 30, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -3.1% | -1.7% | -16.1% | -2.4% | -5.5% | +2.1% | -0.6% | +3.1% | -9.7% | +0.1% | -15.4% | |
| – | -4.5% | +0.4% | -4.1% | +1.1% | -9.5% | +18.1% | +1.8% | +9.4% | -15.8% | -3.8% | +4.5% | |
| – | +27.2% | -29.3% | -11.8% | +115.1% | -29.6% | +41.2% | +81.8% | -9.4% | -16.3% | -22.0% | -12.9% | |
| – | +27.2% | -29.3% | -11.8% | +115.1% | -29.6% | +41.2% | +81.8% | -9.4% | -16.3% | -22.0% | -12.9% | |
| – | -11.8% | +22.3% | -15.9% | -38.2% | +27.4% | +31.8% | -60.8% | +87.3% | -43.7% | +44.4% | +56.3% | |
| – | -7.1% | +1.4% | -4.8% | +1.6% | -3.4% | +0.7% | +7.8% | +5.2% | -3.6% | -4.6% | -7.3% | |
| – | – | – | – | – | -2.8% | -19.4% | -1.7% | -3.0% | -0.5% | – | – | |
| – | -100.0% | – | – | – | – | – | – | – | – | – | – | |
| – | -2.8% | -2.9% | -3.0% | -3.1% | -3.1% | -3.3% | -3.3% | -3.5% | -3.6% | +7.8% | -44.3% | |
| – | -0.9% | -3.9% | -1.1% | -14.0% | -5.7% | -4.5% | +0.9% | -0.3% | -9.4% | +0.2% | -2.7% | |
| – | -1.9% | -3.2% | -1.7% | -62.9% | -29.4% | -31.1% | +13.6% | +7.4% | -3.2% | +12.5% | -17.4% | |
| – | +0.0% | +10.9% | -9.6% | -99.2% | -22.9% | -100.0% | – | -100.0% | – | – | – | |
| – | -0.4% | -10.7% | -4.3% | -14.4% | -25.8% | -4.6% | +9.6% | -9.9% | -3.1% | -29.0% | +27.1% | |
| – | -0.4% | +0.0% | +0.1% | +48.1% | +0.3% | +0.3% | +0.3% | -0.7% | -13.7% | +0.3% | +1.4% | |
| – | -6.9% | +2.2% | -41.8% | +31.6% | -5.0% | +14.5% | -3.0% | +8.6% | -10.3% | +0.1% | -34.7% | |
| – | -178.7% | – | – | – | – | – | – | – | – | – | – | |
| – | +0.2% | +0.6% | +0.8% | +5.7% | -2.5% | +5.7% | -5.4% | +4.2% | -7.3% | +7.8% | -8.7% |
Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.